Tag: GlobeNewswire

Expands product innovation across unified platform at Navigate 2026 delivering the industry’s first real-time defense to discover, govern and protect all human, machine and AI agent identities

Key Announcement Highlights:

• Introducing SailPoint Autonomous Agents: SailPoint debuts three classes of Autonomous Agents that enforce policy, right-size privileges, and protect systems without disrupting legitimate business automation.
• Autonomous Identity Security Posture Management (A-ISPM): New A-ISPM uses the live identity context in SailPoint Atlas to continuously uncover critical exposures across all identity types, then closes the loop with real-time remediation.
• Expanded SailPoint Agentic and Human Fabrics: SailPoint expands its Agentic Fabric to map the entire AI agent surface area—enabling shadow AI discovery, runtime authorization, and instant ‘kill switch’ controls—while simultaneously advancing its Human Fabric with next-generation certifications and segmented identity data to give organizations finer-grained access governance.
• Enhanced Atlas capabilities and Atlas Extensibility framework: New common services, SaaS plug-ins, and Workflow enhancements, including versioning, execution history, and serial loops of up to 1,000 iterations, make Atlas a more unified and extensible foundation for scaling identity security.
• Zero Standing Privilege for humans and machines: New Just-in-Time (JIT) provisioning with conditions, plus effective privilege visibility, replaces always-on access for people, service accounts, and AI agents alike.

AUSTIN, Texas, Oct. 06, 2026 (GLOBE NEWSWIRE) — Today at Navigate 2026, its annual flagship conference, SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, announced significant new capabilities across SailPoint Agentic Fabric™ (SAF) and SailPoint Human Fabric™ (SHF), the two purpose-built products of its Identity Security solution, built on SailPoint Atlas. These innovations give enterprises what they need most in the agentic era: full visibility into every hidden AI tool, continuous compliance across human and machine workflows, the replacement of permanent access keys with temporary permissions, and the transformation of identity security from a static compliance check into real-time, automated defense.

According to the latest SailPoint Horizons of Identity Security report, 79% of enterprises are already running AI agents in production, yet only 2% have deployed identity security tools purpose-built to govern and secure them. Meanwhile, enterprises are stuck between static reviews that are outdated the moment they finish and posture dashboards that flag risks but can’t fix them.

Introducing SailPoint Autonomous Agents
When AI agents invoke MCP tool calls at machine speed, human review of every action is impossible. SailPoint announced Autonomous Agents, a fleet of specialized AI agents built to govern and protect the agentic ecosystem. Unlike generic tools that simply shut agents down when anomalies occur, Autonomous Agents use identity context to tell legitimate intent from malicious activity, stopping threats while keeping productive agents running. These Autonomous Agents actively govern the agentic lifecycle: continuously monitoring runtime actions, intercepting threats, and right-sizing permissions to enforce zero standing privilege at machine speed.

Matt Mills, President of SailPoint, said:
“Autonomous agents are no longer just experimental copilots; they are becoming the primary execution layer of modern enterprises. Enterprises cannot afford to slow down AI innovation out of fear, nor can they afford ungoverned access chaos. Moving beyond Zero Trust to Autonomous Identity allows organizations to master the converged human-plus-AI workforce, eliminate invisible risk, and innovate with complete confidence.”

Chandra Gnanasambandam, EVP of Product and Chief Technology Officer, said:
“The idea that a security admin is going to review and approve access for a group of autonomous agents making 10,000 tool calls a second isn’t just outdated—it’s a fantasy. The only way to govern autonomous machines is with autonomous machine defense. We’ve built Autonomous Agents so enterprises can stop the threat, save the good agents, and bring human and non-human identity into real-time. In a near-AGI world, standing privilege is dead.”

Autonomous Identity Security Posture Management (A-ISPM) goes beyond the dashboard
Using the live identity context in SailPoint Atlas, SailPoint’s new A-ISPM continuously detects dormant accounts, partially offboarded identities, orphaned access, shadow admins, and privileged outliers hidden deep in access paths. It then closes the loop on each organization’s terms, with remediation ranging from one-click fixes, such as revoking access, disabling an identity or AI agent, or assigning an owner, to fully automated policy enforcement.

New automation and global compliance upgrades
SailPoint is advancing global identity security with powerful new updates across its platform. The company introduced new updates to the SailPoint Atlas engine with advanced automation workflows to help enterprises scale security, while also launching IdentityIQ 9.0 to make everyday access governance simpler and more secure for business users. To support this growth, SailPoint is also expanding its global footprint—opening a new data center in South Korea and preparing to meet some of the strictest federal and financial compliance standards, including FedRAMP High, PCI DSS 4.0, and EU Sovereign Cloud.

Delivering four core customer outcomes through new innovations
SailPoint delivers autonomous identity and a host of customer benefits and improved security outcomes across its Identity Security platform. New product innovations showcased at Navigate enable customers to realize these four critical business outcomes:

• Comprehensive discovery: Security teams can’t govern what they can’t see. Every agent, credential, and data store that never reach the identity program becomes access no one owns. New endpoint and browser sensors, SIEM and XDR telemetry, and vault and pipeline NHI discovery bring MCP servers, tools, credentials, and data stores into view. Data Access Security adds classification integrations with Microsoft Purview and BigID, plus new connectors for Atlassian Confluence, Google BigQuery, and AWS Redshift.
• Enabling compliance: Auditors are asking how AI agents are governed, and most organizations can’t yet produce the evidence. New Agent Audit turns agent inventory and governance activity into framework-aligned evidence reports that can be exported in one action, customized, or scheduled, making audit preparation repeatable.
• Strengthening security posture: Standing privilege is invisible risk. Every always-on account is an open door for attackers. Just-in-Time provisioning (JIT-P) grants access only when needed, with conditions such as business justification or reauthentication and activation through Slack or ServiceNow. Agentic Fabric delivers prompt monitoring with policy-based redaction and blocking and behavioral risk detection. Human Fabric features a CrowdStrike Foundry App and SecOps containment actions with a full audit trail.
• Streamlining operations: Governance has become too admin-heavy, and manual processes can’t keep pace with the volume of human and agent access. Human Fabric will now offer next-generation access requests with an embedded Harbor Pilot Access Request Agent. The upcoming Harbor Pilot Policy Agent lets administrators explain and draft access policies for people and agents in plain language, and Agentic Fabric provides one-click agent lifecycle controls and an agent kill switch.

Platform milestone: SailPoint Agentic Fabric + Entro integration
Also announced during Navigate, the Entro Security integration into SailPoint Agentic Fabric will soon be complete. The integration includes Entro-powered credential lineage, exposed secret discovery, and prompt-intent monitoring into Agentic Fabric, extending governance to secrets and credentials that AI agents and NHIs depend on.

Availability
Capabilities across SailPoint Agentic Fabric, SailPoint Human Fabric, and SailPoint Atlas are rolling out globally beginning at Navigate 2026. A-ISPM, the Harbor Pilot Policy Agent, and the Proofpoint integration are expected in Q4 FY27.

New Success Acceleration service packages combine expert-led roadmaps, vertical-specific deployment accelerators, AI-driven risk reduction, and continuous compliance support to help customers reach zero standing privilege and realize value faster.

To watch Navigate 2026 keynotes and product demonstrations live or on demand, visit www.sailpoint.com/navigate.

About SailPoint
SailPoint (Nasdaq: SAIL) is defining the new era of adaptive identity security. In a world where non-human identities now significantly outnumber humans, our AI-powered platform unifies identity, security, and data intelligence to protect today’s enterprise from advanced identity-based threats. We deliver the identity solution that spans both the breadth of identities and the depth of context needed to drive real-time access with confidence. Built on principles like zero-standing privilege and contextualized risk, our SailPoint platform transforms identity from a point of vulnerability into a powerful security advantage. Trusted by many of the world’s leading organizations, SailPoint secures the enterprise with intelligent, autonomous identity security.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to SailPoint’s expectations regarding announcements made at Navigate. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “expects,” “plans,” “anticipates,” “could,” “would,” “plan to,” “intend to,” “believe,” or “goal” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. These forward-looking statements are not guarantees of future performance, but are based on management’s current expectations, assumptions and beliefs concerning future developments and their potential effect on us, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Our expectations expressed or implied in these forward-looking statements may not turn out to be correct. The development, release, and timing of any features or functionality described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if available, basis, may not be delivered at all and should not be relied on in making a purchasing decision, and could be materially different from our expectations because of various risks.

Important factors, some of which are beyond our control, that could cause actual results to differ materially from our historical results or those expressed or implied by these forward-looking statements include the following: our ability to deepen our relationships with existing customers; the growth in the market for identity security solutions; our ability to maintain successful relationships with each of our partners; our ability to compete successfully against current and future competitors; the increasing complexity of our operations; our ability to maintain and enhance our brand or reputation as an industry leader and innovator; unfavorable conditions in our industry or the global economy; our ability to successfully introduce, use, and integrate artificial intelligence (AI) with our solutions; breaches in our security, cyber attacks, or other cyber risks; interruptions, outages, or other disruptions affecting the delivery of our SaaS solution or any of the third-party cloud-based systems that we use in our operations; our ability to adapt and respond to rapidly changing technology, industry standards, regulations, or customer needs, requirements, or preferences; real or perceived errors, failures, or disruptions in our platform or solutions; and the ability of our platform and solutions to effectively interoperate with our customers’ existing or future IT infrastructures.

More information on these risks and other potential factors that could affect our financial results is included in our reports and other documents filed with the Securities and Exchange Commission including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in our most recently filed Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise.

The development, release, and timing of any features, functionality, capabilities, or services described for SailPoint’s products that are not currently available remain at SailPoint’s sole discretion on a when, and if, available basis and may not be delivered at all and must not be relied on in making a purchasing or investing decision.

Media relations for SailPoint
Shannon Paulk
Sr. Manager, Corporate Communications
303-748-2275
shannon.paulk@sailpoint.com

Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives

Pelthos gains enhanced commercial coverage through a regional commercial health plan representing approximately 3 million covered lives

Formulary coverage for ZELSUVMI increases to 127 million commercially covered lives

DURHAM, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos” or the “Company”), today announced that it signed an agreement with a major Pharmacy Benefit Manager (“PBM”) to open access to ZELSUVMI^® (berdazimer) topical gel, 10.3%, covering 24 million covered lives. The Company also received a formulary update enhancing access to ZELSUVMI with a regional health plan that covers approximately 3 million lives. These significant updates have expanded patient access to ZELSUVMI, an important priority for Pelthos. ZELSUVMI now has formulary coverage across 127 million or 69% of commercially covered lives and strong Medicaid coverage of more than 70 million or 100% of covered lives.

“Expanding patient access to ZELSUVMI has been a top priority for Pelthos since we launched the product last July,” said Sai Rangarao, Chief Commercial Officer at Pelthos. “We are pleased with our progress and remain focused on making this effective, convenient treatment available to patients and families affected by molluscum contagiosum.”

This formulary agreement affects one of the largest PBMs in the U.S., which manages prescription drug benefits for employers, health plans and government programs. The PBM serves roughly one in three Americans and added ZELSUVMI to its national formulary without requiring prior authorization, effective October 1, 2026. The second formulary update, which took effect in September, serves roughly 3 million members.

Pelthos launched ZELSUVMI for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older in July 2025. ZELSUVMI is a novel, topical nitric oxide-releasing gel for the treatment of molluscum. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application and can be used to treat molluscum contagiosum infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections.

About Molluscum Contagiosum
Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. This highly contagious viral skin condition afflicts an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States, most of them in children.^1,2,3 Individuals with compromised immune systems are at an elevated risk of contracting molluscum, with the condition impacting approximately 20% of HIV patients.⁴ Molluscum infections spread to others through contact with infected persons or contaminated objects like towels, toys, furniture, swimming pools, and other surfaces. Molluscum infections present with raised, flesh-colored or red bumps that can appear anywhere on the body, including the face, hands, trunk, genitals, back of the knees, armpits, and other sensitive areas. People with molluscum may suffer discomfort from itching, secondary bacterial infections from scratching, or atopic dermatitis, as well as immense social stigma from having visible molluscum lesions that may persist for months to years. It is estimated that 30% of children will have lesions that persist beyond 18 months.⁵ Up to 73% of children with molluscum go untreated.

About ZELSUVMI (berdazimer) topical gel, 10.3%
ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI received a novel drug designation from the U.S. Food and Drug Administration in 2024 and is the first and only approved topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician’s office, or other medical setting to treat this highly contagious viral skin infection. The product was developed using the proprietary nitric oxide-based technology platform, NITRICIL™, now owned by Ligand Pharmaceuticals Incorporated. Complete prescribing information and important safety information is available at www.zelsuvmi.com.

IMPORTANT SAFETY INFORMATION

Contraindications: None.

Warnings: Application site reactions, including, allergic contact dermatitis occurred. Discontinue ZELSUVMI and initiate appropriate therapy.

Adverse Reactions: The most commonly reported adverse reactions (1%) are application site reactions including pain such as burning or stinging sensations (18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%).

Forward-Looking Statements
This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) our belief that the new pharmacy benefit manager agreement will expand patient access to ZELSUVMI, (ii) our plans for continued commercial growth and increased coverage for ZELSUVMI, and (iii) the Company’s future opportunities, strategy and plans in the market. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to our reliance on third-party partners for market access and distribution; the possibility that ZELSUVMI may not achieve market acceptance or broad formulary coverage; our ability to maintain regulatory approvals; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI^® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI^® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE^® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

__________________________________
¹ ZELSUVMI. Prescribing information. LNHC, Inc. 2024.
² Browning JC, Enloe C, Cartwright M, et al. Efficacy and safety of topical nitric oxide-releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2022;158(8):871-878
³ Han H, Smythe C, Yousefian F, Berman B. Molluscum contagiosum virus evasion of immune surveillance: a review. J Drugs Dermatol. 2023;22(2):182-189.
⁴ Neal Bhatia, Adelaide A Hebert, James Q Del Rosso. Comprehensive Management of Molluscum Contagiosum: Assessment of Clinical Associations, Comorbidities, and Management Principles. Journal of Clinical and Aesthetic Dermatology. 2023 Aug;16(8 Suppl 1):S12–S17
⁵ Olsen JR, Gallacher J, Finlay A, Piguet V, Francis NA. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15:190-195

Company secures new formulary coverage with a major Pharmacy Benefit Manager, reaching an additional 24 million covered lives

Pelthos gains enhanced commercial coverage through a regional commercial health plan representing approximately 3 million covered lives

Formulary coverage for ZELSUVMI increases to 127 million commercially covered lives

DURHAM, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos” or the “Company”), today announced that it signed an agreement with a major Pharmacy Benefit Manager (“PBM”) to open access to ZELSUVMI^® (berdazimer) topical gel, 10.3%, covering 24 million covered lives. The Company also received a formulary update enhancing access to ZELSUVMI with a regional health plan that covers approximately 3 million lives. These significant updates have expanded patient access to ZELSUVMI, an important priority for Pelthos. ZELSUVMI now has formulary coverage across 127 million or 69% of commercially covered lives and strong Medicaid coverage of more than 70 million or 100% of covered lives.

“Expanding patient access to ZELSUVMI has been a top priority for Pelthos since we launched the product last July,” said Sai Rangarao, Chief Commercial Officer at Pelthos. “We are pleased with our progress and remain focused on making this effective, convenient treatment available to patients and families affected by molluscum contagiosum.”

This formulary agreement affects one of the largest PBMs in the U.S., which manages prescription drug benefits for employers, health plans and government programs. The PBM serves roughly one in three Americans and added ZELSUVMI to its national formulary without requiring prior authorization, effective October 1, 2026. The second formulary update, which took effect in September, serves roughly 3 million members.

Pelthos launched ZELSUVMI for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older in July 2025. ZELSUVMI is a novel, topical nitric oxide-releasing gel for the treatment of molluscum. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application and can be used to treat molluscum contagiosum infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections.

About Molluscum Contagiosum
Molluscum is a poxvirus and one of the most common skin infections seen by dermatologists, pediatric dermatologists, and pediatricians. This highly contagious viral skin condition afflicts an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States, most of them in children.^1,2,3 Individuals with compromised immune systems are at an elevated risk of contracting molluscum, with the condition impacting approximately 20% of HIV patients.⁴ Molluscum infections spread to others through contact with infected persons or contaminated objects like towels, toys, furniture, swimming pools, and other surfaces. Molluscum infections present with raised, flesh-colored or red bumps that can appear anywhere on the body, including the face, hands, trunk, genitals, back of the knees, armpits, and other sensitive areas. People with molluscum may suffer discomfort from itching, secondary bacterial infections from scratching, or atopic dermatitis, as well as immense social stigma from having visible molluscum lesions that may persist for months to years. It is estimated that 30% of children will have lesions that persist beyond 18 months.⁵ Up to 73% of children with molluscum go untreated.

About ZELSUVMI (berdazimer) topical gel, 10.3%
ZELSUVMI (berdazimer) topical gel, 10.3% is a nitric oxide (NO) releasing agent indicated for the topical treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI received a novel drug designation from the U.S. Food and Drug Administration in 2024 and is the first and only approved topical prescription medication that can be applied by patients, parents, or caregivers at home, outside of a physician’s office, or other medical setting to treat this highly contagious viral skin infection. The product was developed using the proprietary nitric oxide-based technology platform, NITRICIL™, now owned by Ligand Pharmaceuticals Incorporated. Complete prescribing information and important safety information is available at www.zelsuvmi.com.

IMPORTANT SAFETY INFORMATION

Contraindications: None.

Warnings: Application site reactions, including, allergic contact dermatitis occurred. Discontinue ZELSUVMI and initiate appropriate therapy.

Adverse Reactions: The most commonly reported adverse reactions (1%) are application site reactions including pain such as burning or stinging sensations (18.7%), erythema (11.7%), pruritus (5.7%), exfoliation (5.0%), dermatitis (4.9%), swelling (3.5%), erosion (1.6%), discoloration (1.5%), vesicles (1.5%), irritation (1.2%), and infection (1.1%).

Forward-Looking Statements
This press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos’ current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) our belief that the new pharmacy benefit manager agreement will expand patient access to ZELSUVMI, (ii) our plans for continued commercial growth and increased coverage for ZELSUVMI, and (iii) the Company’s future opportunities, strategy and plans in the market. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to our reliance on third-party partners for market access and distribution; the possibility that ZELSUVMI may not achieve market acceptance or broad formulary coverage; our ability to maintain regulatory approvals; and changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.

About Pelthos Therapeutics
Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease products that address unmet patient needs. ZELSUVMI^® (berdazimer) topical gel, 10.3%, the company’s lead product, is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum contagiosum. The company’s portfolio of assets includes XEPI^® (ozenoxacin) Cream, 1%, a topical treatment for impetigo, and XEGLYZE^® (abametapir), a topical treatment for head lice. More information is available at www.pelthos.com. Follow Pelthos on LinkedIn and X.

Contacts

Investors:
LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Media:
KWM Communications
Kellie Walsh
pelthos@kwmcommunications.com
(914) 315-6072

__________________________________
¹ ZELSUVMI. Prescribing information. LNHC, Inc. 2024.
² Browning JC, Enloe C, Cartwright M, et al. Efficacy and safety of topical nitric oxide-releasing berdazimer gel in patients with molluscum contagiosum: a phase 3 randomized clinical trial. JAMA Dermatol. 2022;158(8):871-878
³ Han H, Smythe C, Yousefian F, Berman B. Molluscum contagiosum virus evasion of immune surveillance: a review. J Drugs Dermatol. 2023;22(2):182-189.
⁴ Neal Bhatia, Adelaide A Hebert, James Q Del Rosso. Comprehensive Management of Molluscum Contagiosum: Assessment of Clinical Associations, Comorbidities, and Management Principles. Journal of Clinical and Aesthetic Dermatology. 2023 Aug;16(8 Suppl 1):S12–S17
⁵ Olsen JR, Gallacher J, Finlay A, Piguet V, Francis NA. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15:190-195

BROOKFIELD, NEWS, Oct. 06, 2026 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners will hold its third quarter 2026 conference call and webcast on Friday, November 6, 2026, at 9:00 a.m. (ET).

Results will be released that morning before 7:00 a.m. (ET) and will be available on our website at https://bip.brookfield.com.

Participants can join by conference call or webcast.

Conference Call

• Please pre-register at: BIP2026Q3ConferenceCall
• Upon registering, you will be emailed a dial-in number and unique PIN. This process will bypass the operator and avoid the queue.

Webcast

• Please join and register at: BIP2026Q3Webcast

About Brookfield Infrastructure

Brookfield Infrastructure is a leading global infrastructure company that owns and operates high-quality, long-life assets in the utilities, transport, midstream and data sectors across the Americas, Asia Pacific and Europe. We are focused on assets that have contracted and regulated revenues that generate predictable and stable cash flows. Investors can access its portfolio either through Brookfield Infrastructure Partners L.P. (NYSE: BIP; TSX: BIP.UN), a Bermuda-based limited partnership, or Brookfield Infrastructure Corporation (NYSE, TSX: BIPC), a Canadian corporation. Further information is available at https://bip.brookfield.com.

Brookfield Infrastructure is the flagship listed infrastructure company of Brookfield Asset Management, a global alternative asset manager, headquartered in New York with over $1 trillion of assets under management. For more information, go to https://brookfield.com.

Contact Information

Media John Hamlin Director, Communications Tel: +44 204 557 4334 Email: john.hamlin@brookfield.com

Investor Relations Stephen Fukuda Managing Director, Corporate Development & Investor Relations Tel: +1 (416) 956 5129 Email: stephen.fukuda@brookfield.com

BROOKFIELD, NEWS, Oct. 06, 2026 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners will hold its third quarter 2026 conference call and webcast on Friday, November 6, 2026, at 9:00 a.m. (ET).

Results will be released that morning before 7:00 a.m. (ET) and will be available on our website at https://bip.brookfield.com.

Participants can join by conference call or webcast.

Conference Call

• Please pre-register at: BIP2026Q3ConferenceCall
• Upon registering, you will be emailed a dial-in number and unique PIN. This process will bypass the operator and avoid the queue.

Webcast

• Please join and register at: BIP2026Q3Webcast

About Brookfield Infrastructure

Brookfield Infrastructure is a leading global infrastructure company that owns and operates high-quality, long-life assets in the utilities, transport, midstream and data sectors across the Americas, Asia Pacific and Europe. We are focused on assets that have contracted and regulated revenues that generate predictable and stable cash flows. Investors can access its portfolio either through Brookfield Infrastructure Partners L.P. (NYSE: BIP; TSX: BIP.UN), a Bermuda-based limited partnership, or Brookfield Infrastructure Corporation (NYSE, TSX: BIPC), a Canadian corporation. Further information is available at https://bip.brookfield.com.

Brookfield Infrastructure is the flagship listed infrastructure company of Brookfield Asset Management, a global alternative asset manager, headquartered in New York with over $1 trillion of assets under management. For more information, go to https://brookfield.com.

Contact Information

Media John Hamlin Director, Communications Tel: +44 204 557 4334 Email: john.hamlin@brookfield.com

Investor Relations Stephen Fukuda Managing Director, Corporate Development & Investor Relations Tel: +1 (416) 956 5129 Email: stephen.fukuda@brookfield.com

Transactions during 29 September 2026 – 05 October 2026
On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.

The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.

The following transactions were made under the share buy-back program 29 September – 05 October 2026:

	Number of shares bought	Average purchase price	Amount (DKK)
Accumulated, last announcement 29 September 2026 30 September 2026 01 October 2026 02 October 2026 05 October 2026	14,349,667 240,000  275,000  200,000  122,000  18,683	16.45 16.26 16.38 16.15 16.11 16.78	236,115,285 3,901,392 4,504,748 3,230,000 1,964,871 313,416
Total, 29 September – 05 October 2026	855,683	16.26	13,914,427
Accumulated under the program	15,205,350	16.44	250,029,712

With the transactions stated above Alm. Brand A/S holds a total of 47,942,022 own shares, corresponding to 3.41% of the total number of outstanding shares.

Contact
Please direct any questions regarding this announcement to:

Investors and equity analysts:                                 

VP, Head of Investor Relations & ESG                    
Mads Thinggaard                                                       
Mobile no, +45 2025 5469                                      

Attachments

• Alm Brand_Share buyback 29 September – 05 October 2026
• AS 55 2026 – Transactions under share buyback program

Transactions during 29 September 2026 – 05 October 2026
On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.

The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.

The following transactions were made under the share buy-back program 29 September – 05 October 2026:

	Number of shares bought	Average purchase price	Amount (DKK)
Accumulated, last announcement 29 September 2026 30 September 2026 01 October 2026 02 October 2026 05 October 2026	14,349,667 240,000  275,000  200,000  122,000  18,683	16.45 16.26 16.38 16.15 16.11 16.78	236,115,285 3,901,392 4,504,748 3,230,000 1,964,871 313,416
Total, 29 September – 05 October 2026	855,683	16.26	13,914,427
Accumulated under the program	15,205,350	16.44	250,029,712

With the transactions stated above Alm. Brand A/S holds a total of 47,942,022 own shares, corresponding to 3.41% of the total number of outstanding shares.

Contact
Please direct any questions regarding this announcement to:

Investors and equity analysts:                                 

VP, Head of Investor Relations & ESG                    
Mads Thinggaard                                                       
Mobile no, +45 2025 5469                                      

Attachments

• Alm Brand_Share buyback 29 September – 05 October 2026
• AS 55 2026 – Transactions under share buyback program

Three months after its official kick-off in Brussels, the Q-PLANET Pilot Line is moving from vision to execution, with Pasqal steering 28 partners from 11 European countries to build a resilient European supply chain for neutral-atom quantum technologies

PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE) — Pasqal (NASDAQ: PSQL), a global leader in neutral-atom quantum computing, is coordinating the implementation of Q-PLANET (Quantum Pilot Line for production of Advanced chips for Neutral atom European Technologies), co-funded by the EU Chips Joint Undertaking (Chips JU) and National/Regional authorities. Backed by €50 million over three years, the consortium brings together 28 partners from 11 European countries to develop industrial-grade chip components for neutral-atom quantum computing, sensing, and communication.

A Concrete Commitment to Europe’s Quantum Industrial Ambitions and Strategic Autonomy

Pasqal’s leadership of Q-PLANET reflects the company’s concrete commitment to the European Union’s industrial quantum ambitions, in line with the upcoming EU Quantum Act. Through Q-PLANET, Pasqal is delivering one of the flagship initiatives of the European Quantum Strategy, aimed at supporting the large-scale industrialization of quantum technologies across the European Union.

Through this pan-European collaborative effort, Q-PLANET will help establish the foundations for a resilient, state-of-the-art European quantum supply chain, strengthening the broader resilience and strategic autonomy of the European Union, while reinforcing its global competitiveness in quantum technologies.

Over the next three years, the consortium will develop critical industrial-grade chip-based components for neutral-atom quantum technologies, including lasers at four key wavelengths (461 nm, 698 nm, 795 nm and 1013 nm), atom chips for quantum sensing and computing, and microfabricated vapor cells for atomic clocks and field sensors. Q-PLANET will also establish a pathway from laboratory research to industrial fabrication through the development of standardized Process Design Kits (PDKs) and Assembly Design Kits (ADKs), alongside energy-efficiency monitoring assessment across the production cycle of quantum technologies. Within this effort, Pasqal will notably lead the development activities dedicated to chip-based laser sources at 1013nm, one of the project’s core technology streams. Pasqal will also act as an end-user of the microfabricated vapor cells and laser sources, providing top-level specifications for their development, testing and validation.

Strengthening Europe’s Neutral-atom Ecosystem & Building a European Quantum Market around User Needs

Under Pasqal’s leadership, Q-PLANET will strengthen the European industrial and scientific neutral-atom ecosystem by bringing together leading research and technology organizations, industry partners and academic research groups. With 28 partners from 11 European countries, the consortium will foster synergies and partnerships across academia and industry, helping connect scientific research, industrial capabilities and the development of real-world quantum applications.

Q-PLANET will also contribute to the development of a European quantum market by addressing the needs of European users. Through advancements in quantum computing, quantum sensing and quantum communications, the pilot line will help lay the foundations for future quantum use case applications in sectors where societal, economic and scientific interests are particularly strong, including drug discovery and materials discovery. By connecting advances in quantum hardware and manufacturing with concrete application requirements, Q-PLANET will help bring European quantum technologies closer to practical deployment and adoption.

“Three months after our kick-off in Brussels, Q-PLANET has moved from ambition to execution. Together with our 28 partners, we are building a European supply chain for neutral-atom technologies, while bringing quantum industrialization closer to concrete user needs,” said Loïc Henriet, CTO of Pasqal. “Q-PLANET reflects Pasqal’s commitment to Europe’s quantum ambitions, bridging large-scale industrialization rooted in resilient capabilities with real-world application to build a globally competitive and resilient European quantum industry.”

Contact:
Investors 
investors@pasqal.com

Media
pr@pasqal.com

About Pasqal
Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future.

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network).

In Europe, under the EuroHPC Joint Undertaking procurement process, Pasqal has delivered three quantum processing units to European High-Performance Computing Centers in France (TGCC), Germany (Forschungszentrum Jülich) and Italy (CINECA). Pasqal is the elected European Convenor of CEN/CENELEC JTC22 European standardization WG3 on quantum computing and simulation, representing 34 European countries. It is also a member of the French governmental delegation to the ISO/IEC JTC3 international standardization committee on quantum technologies.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or Chips Joint Undertaking. Neither the European Union nor the granting authority can be held responsible for them. The project is supported by Chips JU and its members including top-up funding by France 2030, European Regional Development Fund (ERDF), Ministry of Science, Research and Arts Baden-Württemberg, Business Finland and The Austrian Research Promotion Agency (FFG).

Read more about Q-PLANET: www.q-planet.eu

Three months after its official kick-off in Brussels, the Q-PLANET Pilot Line is moving from vision to execution, with Pasqal steering 28 partners from 11 European countries to build a resilient European supply chain for neutral-atom quantum technologies

PARIS, Oct. 06, 2026 (GLOBE NEWSWIRE) — Pasqal (NASDAQ: PSQL), a global leader in neutral-atom quantum computing, is coordinating the implementation of Q-PLANET (Quantum Pilot Line for production of Advanced chips for Neutral atom European Technologies), co-funded by the EU Chips Joint Undertaking (Chips JU) and National/Regional authorities. Backed by €50 million over three years, the consortium brings together 28 partners from 11 European countries to develop industrial-grade chip components for neutral-atom quantum computing, sensing, and communication.

A Concrete Commitment to Europe’s Quantum Industrial Ambitions and Strategic Autonomy

Pasqal’s leadership of Q-PLANET reflects the company’s concrete commitment to the European Union’s industrial quantum ambitions, in line with the upcoming EU Quantum Act. Through Q-PLANET, Pasqal is delivering one of the flagship initiatives of the European Quantum Strategy, aimed at supporting the large-scale industrialization of quantum technologies across the European Union.

Through this pan-European collaborative effort, Q-PLANET will help establish the foundations for a resilient, state-of-the-art European quantum supply chain, strengthening the broader resilience and strategic autonomy of the European Union, while reinforcing its global competitiveness in quantum technologies.

Over the next three years, the consortium will develop critical industrial-grade chip-based components for neutral-atom quantum technologies, including lasers at four key wavelengths (461 nm, 698 nm, 795 nm and 1013 nm), atom chips for quantum sensing and computing, and microfabricated vapor cells for atomic clocks and field sensors. Q-PLANET will also establish a pathway from laboratory research to industrial fabrication through the development of standardized Process Design Kits (PDKs) and Assembly Design Kits (ADKs), alongside energy-efficiency monitoring assessment across the production cycle of quantum technologies. Within this effort, Pasqal will notably lead the development activities dedicated to chip-based laser sources at 1013nm, one of the project’s core technology streams. Pasqal will also act as an end-user of the microfabricated vapor cells and laser sources, providing top-level specifications for their development, testing and validation.

Strengthening Europe’s Neutral-atom Ecosystem & Building a European Quantum Market around User Needs

Under Pasqal’s leadership, Q-PLANET will strengthen the European industrial and scientific neutral-atom ecosystem by bringing together leading research and technology organizations, industry partners and academic research groups. With 28 partners from 11 European countries, the consortium will foster synergies and partnerships across academia and industry, helping connect scientific research, industrial capabilities and the development of real-world quantum applications.

Q-PLANET will also contribute to the development of a European quantum market by addressing the needs of European users. Through advancements in quantum computing, quantum sensing and quantum communications, the pilot line will help lay the foundations for future quantum use case applications in sectors where societal, economic and scientific interests are particularly strong, including drug discovery and materials discovery. By connecting advances in quantum hardware and manufacturing with concrete application requirements, Q-PLANET will help bring European quantum technologies closer to practical deployment and adoption.

“Three months after our kick-off in Brussels, Q-PLANET has moved from ambition to execution. Together with our 28 partners, we are building a European supply chain for neutral-atom technologies, while bringing quantum industrialization closer to concrete user needs,” said Loïc Henriet, CTO of Pasqal. “Q-PLANET reflects Pasqal’s commitment to Europe’s quantum ambitions, bridging large-scale industrialization rooted in resilient capabilities with real-world application to build a globally competitive and resilient European quantum industry.”

Contact:
Investors 
investors@pasqal.com

Media
pr@pasqal.com

About Pasqal
Pasqal (Nasdaq: PSQL) helps organizations tackle problems that are difficult or impossible to solve with conventional computing methods alone. Founded in 2019 on Nobel Prize–winning research, Pasqal builds and operates neutral-atom quantum computers, delivered with a full software stack, for industry, science, and governments. Pasqal’s production-ready systems are available both on-premises and through the cloud, enabling organizations to harness quantum computing without requiring in-house quantum expertise. A single hardware platform supports analog workloads today and is designed to evolve toward fault-tolerant quantum computing in the future.

Headquartered in France with operations globally, Pasqal’s quantum computing systems are used by customers across energy, financial services and advanced materials to address complex challenges. Pasqal’s customers include Saudi Aramco, Crédit Agricole CIB, LG Electronics and supported by partnerships with NVIDIA and IBM (Pasqal is part of the IBM Quantum Network).

In Europe, under the EuroHPC Joint Undertaking procurement process, Pasqal has delivered three quantum processing units to European High-Performance Computing Centers in France (TGCC), Germany (Forschungszentrum Jülich) and Italy (CINECA). Pasqal is the elected European Convenor of CEN/CENELEC JTC22 European standardization WG3 on quantum computing and simulation, representing 34 European countries. It is also a member of the French governmental delegation to the ISO/IEC JTC3 international standardization committee on quantum technologies.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or Chips Joint Undertaking. Neither the European Union nor the granting authority can be held responsible for them. The project is supported by Chips JU and its members including top-up funding by France 2030, European Regional Development Fund (ERDF), Ministry of Science, Research and Arts Baden-Württemberg, Business Finland and The Austrian Research Promotion Agency (FFG).

Read more about Q-PLANET: www.q-planet.eu

Purchases are the next step in the Company’s $1.2 billion dual treasury capital plan targeting $827 million in Bitcoin and $800 million in AI assets by FY2031.

SINGAPORE, Oct. 06, 2026 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group”, “GNS” or the “Company”), a leading AI-powered education group, today announced that it has recommenced its Bitcoin Treasury purchases, acquiring 10 Bitcoin for approximately $854,000 at an average price of $85,364 per BTC between October 2 and October 5, 2026.

The purchases mark a strategic milestone for the Company as it takes the next step in executing its Board-approved $1.2 billion dual treasury capital plan, announced on August 27, 2026. The plan targets $827 million allocated to Bitcoin and $800 million to AI assets, with a goal of reaching $2 billion in total assets by FY2031.

The recommencement of Bitcoin purchases follows the ruling by U.S. Court of Appeals for the Second Circuit on August 31, 2026, vacating the preliminary injunction that had previously blocked the Company from issuing shares, raising funds, and purchasing Bitcoin.

The Company had previously indicated that it intended to recommence Bitcoin purchases in October 2025, citing the Company’s belief that this coincided with the early stages of Bitcoin’s historic four-year halving-cycle uptrend.

The Company intends to continue accumulating Bitcoin on an ongoing basis as part of its dual treasury strategy, alongside its planned accumulation of AI stocks. To date, the Company has announced look-through interests in OpenAI, Anthropic, Databricks, SpaceX (held prior to and following its IPO on June 12, 2026) and other Pre-IPO frontier AI companies.

The Company intends to fund purchases for its dual treasury through a balanced mix of operating cash flow, previously-announced plans for the issuance of perpetual preferred securities and prudent use of its At-The-Market Program facility, designed to maximise Net Asset Value Per Share (NAVPS). The Company currently has no plans to fund purchases with debt financing, or to hypothecate any of its Bitcoin or AI stocks held in its dual treasury.

Roger James Hamilton, CEO of Genius Group, said “This week’s purchase of Bitcoin, while modest, is a signal to our shareholders and to the market that we are recommencing our Bitcoin accumulation strategy at what we believe is the early stages of Bitcoin’s next major uptrend.”

“We are educating our students on the ‘ABC’s of the future: AI, Blockchain and Community, in which we believe ownership in the future AI-powered digital workforce and Blockchain-based digital economy is a key component to wealth creation in a post-Singularity world. Our dual treasury strategy is our way of leading by example, as we continue to pursue our mission of preparing humanity for a fast changing future.”

About Genius Group

Genius Group (NYSE: GNS) is a global education group delivering AI powered, education and acceleration solutions for the future of work. Genius Group serves 6 million users in over 100 countries through its Genius City model and online digital marketplace of AI training, AI tools and AI talent. It provides personalized, entrepreneurial AI pathways combining human talent with AI skills and AI solutions at the individual, enterprise and government level. To learn more, please visit geniusgroup.ai

Forward-Looking Statements 

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements can be identified by the use of words such as “may,” “will”, “plan,” “should,” “expect,” “anticipate,” “estimate,” “continue,” or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading “Risk Factors” in the Company’s Annual Reports on Form 20-F, as may be supplemented or amended by the Company’s Reports of a Foreign Private Issuer on Form 6-K. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. No information in this press release should be construed as any indication whatsoever of the Company’s future revenues, results of operations, or stock price.

Contacts
For enquiries, contact investor@geniusgroup.ai